0001567619-18-007785.txt : 20181212 0001567619-18-007785.hdr.sgml : 20181212 20181212171453 ACCESSION NUMBER: 0001567619-18-007785 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181210 FILED AS OF DATE: 20181212 DATE AS OF CHANGE: 20181212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burstein Jennifer CENTRAL INDEX KEY: 0001640069 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36562 FILM NUMBER: 181231508 MAIL ADDRESS: STREET 1: C/O LOXO ONCOLOGY, INC. STREET 2: ONE LANDMARK SQUARE, SUITE 1122 CITY: STAMFORD STATE: CT ZIP: 06901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Loxo Oncology, Inc. CENTRAL INDEX KEY: 0001581720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462996673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-653-3880 MAIL ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 4 1 doc1.xml FORM 4 X0306 4 2018-12-10 0 0001581720 Loxo Oncology, Inc. LOXO 0001640069 Burstein Jennifer C/O LOXO ONCOLOGY, INC. ONE LANDMARK SQUARE, SUITE 1122 STAMFORD CT 06901 0 1 0 0 Senior VP of Finance Common Stock 2018-12-10 4 M 0 1250 11.35 A 1250 D Common Stock 2018-12-10 4 S 0 100 130.79 D 1150 D Common Stock 2018-12-10 4 S 0 400 132.44 D 750 D Common Stock 2018-12-10 4 S 0 100 133.34 D 650 D Common Stock 2018-12-10 4 S 0 550 134.71 D 100 D Common Stock 2018-12-10 4 S 0 100 136.04 D 0 D Common Stock 2018-12-11 4 M 0 1250 11.35 A 1250 D Common Stock 2018-12-11 4 S 0 200 135.69 D 1050 D Common Stock 2018-12-11 4 S 0 587 136.98 D 463 D Common Stock 2018-12-11 4 S 0 263 137.88 D 200 D Common Stock 2018-12-11 4 S 0 100 139.36 D 100 D Common Stock 2018-12-11 4 S 0 100 140.48 D 0 D Employee Stock Option (Right to Buy) 11.35 2018-12-10 4 M 0 1250 0 D 2025-04-30 Common Stock 1250 18750 D Employee Stock Option (Right to Buy) 11.35 2018-12-11 4 M 0 1250 0 D 2025-04-30 Common Stock 1250 17500 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Represents the aggregate of sales effected on the same day at different prices. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.20 to $132.85 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.40 to $135.06 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.28 to $136.09 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.45 to $137.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.50 to $138.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, May 1, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments. /s/Jennifer Burstein 2018-12-12